Clinical Trial Update: Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating rosuvastatin to prevent anthracycline-induced cardiotoxicity in breast cancer patients; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracycline-induced Cardiotoxicity
• Breast Cancer

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Shiraz University of Medical Sciences | Conditions: Anthracycline-induced Cardiac Toxicity, Breast Cancer | Phase 4 | Status: NOT_YET_RECRUITING